Drug Development Based on Genome Editing Technology Receives Funding Boost

Each repetition is followed by short segments of "spacer DNA" from previous exposures to a bacterial virus or plasmid. CRISPRs are found in approximately 40% of sequenced bacteria genomes and 90% of sequenced archaea. CRISPRs are often associated with cas genes that code for proteins related to CRISPRs. The CRISPR/Cas complex comprises a prokaryotic immune system that confers resistance to foreign genetic elements such as plasmids and phages and provides a form of acquired immunity. Since 2013, the CRISPR/Cas system has been used in research for gene editing (adding, disrupting, or changing the sequence of specific genes) and gene regulation. By delivering the Cas9 protein and appropriate guide RNAs into a cell, the organism's genome can be cut at any desired location. The conventional CRISPR-Cas9 system is composed of two parts: the Cas9 enzyme, which cleaves the DNA molecule and specific RNA guides (CRISPRs) that shepherd the Cas9 protein to the target gene on a DNA strand.

The biopharmaceutical company CRISPR Therapeutics (Cambridge, MA, USA) announced the accumulation of an additional 38 million USD, which closed its latest round of Series B financing. This additional investment brought the total Series B financing to nearly 140 million USD.

The previous Series B investment was led by Vertex Pharmaceuticals and Bayer Global Investments, an affiliate of Bayer AG, as part of the company’s strategic investment in CRISPR Therapeutics. This second round included several new institutional investors and specialized healthcare funds including Franklin Templeton Investments, New Leaf Venture Partners, funds advised by Clough Capital Partners, and Wellington Capital Management.

“We are very pleased to add these top tier institutional investors in the most recent closing of our Series B financing,” said Dr. Rodger Novak, CEO of CRISPR Therapeutics. “Along with the recent investments made by our strategic partners, Vertex and Bayer, we believe this further investment represents a strong validation of our approach to translate the novel CRISPR/Cas9 gene-editing technology into life-changing medicines for patients. We plan to use these proceeds to advance our current and future programs to the clinic and to expand our research and development organization in Cambridge, Massachusetts.”

Related Links:
CRISPR Therapeutics